Ignas Masilionis
Overview
Explore the profile of Ignas Masilionis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
956
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fu Y, Land M, Kavlashvili T, Cui R, Kim M, DeBitetto E, et al.
Cell
. 2025 Mar;
PMID: 40068680
Recent breakthroughs in the genetic manipulation of mitochondrial DNA (mtDNA) have enabled precise base substitutions and the efficient elimination of genomes carrying pathogenic mutations. However, reconstituting mtDNA deletions linked to...
2.
Moorman A, Benitez E, Cambuli F, Jiang Q, Mahmoud A, Lumish M, et al.
Nature
. 2025 Jan;
637(8047):E28.
PMID: 39789339
No abstract available.
3.
Moorman A, Moorman A, Benitez E, Benitez E, Cambuli F, Cambulli F, et al.
Nature
. 2024 Oct;
637(8047):947-954.
PMID: 39478232
As cancers progress, they become increasingly aggressive-metastatic tumours are less responsive to first-line therapies than primary tumours, they acquire resistance to successive therapies and eventually cause death. Mutations are largely...
4.
Fu Y, Land M, Cui R, Kavlashvili T, Kim M, Lieber T, et al.
bioRxiv
. 2024 Oct;
PMID: 39463974
Highlights: Combining prokaryotic end-joining with targeted endonucleases generates specific mtDNA deletions in human cellsEngineering a panel of cell lines with a large-scale deletion that spans the full spectrum of heteroplasmy75%...
5.
Zaidi S, Park J, Chan J, Roudier M, Zhao J, Gopalan A, et al.
Proc Natl Acad Sci U S A
. 2024 Jul;
121(28):e2322203121.
PMID: 38968122
Targeting cell surface molecules using radioligand and antibody-based therapies has yielded considerable success across cancers. However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules,...
6.
Zaidi S, Park J, Chan J, Roudier M, Zhao J, Gopalan A, et al.
bioRxiv
. 2024 Apr;
PMID: 38645034
Targeting cell surface molecules using radioligand and antibody-based therapies has yielded considerable success across cancers. However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules,...
7.
Tsanov K, Barriga F, Ho Y, Alonso-Curbelo D, Livshits G, Koche R, et al.
bioRxiv
. 2024 Apr;
PMID: 38562717
Driver gene mutations can increase the metastatic potential of the primary tumor, but their role in sustaining tumor growth at metastatic sites is poorly understood. A paradigm of such mutations...
8.
Yamada M, Keller R, Gutierrez R, Cameron D, Suzuki H, Sanghrajka R, et al.
Sci Adv
. 2024 Mar;
10(12):eadn4649.
PMID: 38517960
Genomic rearrangements are a hallmark of most childhood tumors, including medulloblastoma, one of the most common brain tumors in children, but their causes remain largely unknown. Here, we show that...
9.
Nazaret A, Fan J, Lavallee V, Burdziak C, Cornish A, Kiseliovas V, et al.
bioRxiv
. 2023 Nov;
PMID: 38014231
Biological insights often depend on comparing conditions such as disease and health, yet we lack effective computational tools for integrating single-cell genomics data across conditions or characterizing transitions from normal...
10.
DeWolf S, Elhanati Y, Nichols K, Waters N, Nguyen C, Slingerland J, et al.
Sci Transl Med
. 2023 Jul;
15(706):eabq0476.
PMID: 37494469
T cells are the central drivers of many inflammatory diseases, but the repertoire of tissue-resident T cells at sites of pathology in human organs remains poorly understood. We examined the...